What kind of medicine is enzalutamide (enzalutamide) mainly used to treat what diseases?

Enzalutamide (Enzalutamide) is an oral nonsteroidal androgen receptor inhibitor and belongs to a new generation of antiandrogens. It effectively blocks the signaling of androgen receptors through multiple mechanisms, including preventing androgens from binding to the receptors, inhibiting the receptors from entering the nucleus, and hindering the binding of the receptors to DNA, thereby blocking the growth and spread of androgen-dependent tumor cells.

Enzalutamide is mainly used to treat prostate cancer, especially castration-resistant prostate cancer (CRPC). Prostate cancer is an androgen-dependent tumor. In the early stage, the disease can be controlled by inhibiting the production or action of androgens. However, as the disease progresses, the tumor may become castration-resistant, making traditional hormone therapy ineffective. Enzalutamide plays a key role at this stage, delaying tumor development and improving patient survival and quality of life.

Clinical studies have shown that enzalutamide can significantly prolong progression-free survival and overall survival in patients with castration-resistant prostate cancer. It has good safety profile, and common side effects include fatigue, hot flashes, headaches, and high blood pressure. Compared with early anti-androgens, enzalutamide inhibits androgen receptors more completely and can delay the development of drug resistance.

In summary, enzalutamide, as an important targeted drug in modern prostate cancer treatment, is widely used in castration-resistant patients. It not only brings new treatment hope to patients, but also promotes innovation in prostate cancer treatment models. In the future, with the accumulation of clinical experience, the indications and combination treatment options of enzalutamide are expected to be further expanded.

Reference materials:https://www.drugs.com/